Increased CD8+ T-cells have also been shown to predict improved clinical outcome, with higher intratumoral CD8+ T-cell infiltrate associated with improved breast cancer specific survival (HR 0.55 95 % CI, 0.39 to 0.78 p = 0.001) in one large study of 1334 patients [13]. This evidence concerns the gene CD8A and breast carcinoma.